News | July 14, 2011

Endosense, Siemens Complete First Case Using Jointly Developed Contact-Force Visualization


July 14, 2011 – Endosense, a Swiss medical technology company, announced completion of the first patient case using prototype software integrating the contact-force data provided by Endosense’s TactiCath force-sensing ablation catheter with Siemens Healthcare’s electrophysiology solutions.

Performed by Dipen Shah, M.D.,  June 15, 2011, at the University Hospital of Geneva, this procedure demonstrated the feasibility of the companies’ jointly developed application for use during the catheter ablation treatment of cardiac arrhythmias.

The new software was designed to give electrophysiologists access to contact-force information in a fluoroscopically enabled, three-dimensional anatomic heart model with X-ray based catheter tracking system.

“This new contact-force visualization software brings a valuable new sensory dimension to the catheter ablation procedure, as we can now measure, control and also virtually see in 3-D the contact forces we apply as we are applying them,” said Shah. “I believe this new level of visualization will not only make the procedure more intuitive and easier for electrophysiologists to perform, but it will also allow us to improve our ablation technique in such a way that we ultimately offer safer and more effective procedures.”

 

For more information: www.siemens.com/healthcare or www.endosense.com


Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now